Jazz plays coda to blood cancer approval, securing FDA nod for revised dosing schedule

Jazz Pharmaceuticals has won FDA approval for a revised dosing schedule for its blood cancer therapy Rylaze, giving physicians the option to prescribe intramuscular doses of the drug on Monday, Wednesday and Friday.